Richard E. Greenberg

Fox Chase Cancer Center — United States

Medicine · Health Sciences

57h-index12.5kcitations346works74.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bladder and Urothelial Cancer Treatments(134), Renal cell carcinoma treatment(119), Renal and related cancers(73), Urinary and Genital Oncology Studies(62), Prostate Cancer Diagnosis and Treatment(51)

Publications344 total

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)
Journal of Clinical Oncology·2024· 28 cited
Bladder Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network·2024· 189 citedOpen Access
Symptomatic and functional recovery after transurethral resection of bladder tumor: Data from ecological momentary symptom assessment
Urologic Oncology Seminars and Original Investigations·2024· 5 citedOpen Access
Real‐time estimation of nephron activity with a linear measurement system (RENAL‐MS) predicts postoperative estimated glomerular filtration rate
British Journal of Urology·2023· 4 citedOpen Access
Clinical Performance of Technetium-99m–Sestamibi SPECT/CT Imaging in Differentiating Oncocytic Tumors From Renal Cell Carcinoma in Routine Clinical Practice
The Journal of Urology·2023· 21 cited
Supplementary Figure Legend from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S1 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Data from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Figure Legend from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S1 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S3 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Data from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S2 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S3 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
Supplementary Table S2 from A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
2023Open Access
PD15-10 OUTCOMES FOR PATIENTS UNDERGOING SPACEOAR PLACEMENT IN THE SALVAGE RADIATION THERAPY SETTING
The Journal of Urology·2023
A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN).
Journal of Clinical Oncology·2023· 36 cited
A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study
European Urology·2023· 48 citedOpen Access
Pathological and Clinical Outcomes in a Large Surveillance and Intervention Cohort of Radiographically Cystic Renal Masses
The Journal of Urology·2023· 15 cited
No difference in renal function outcomes for patients with oncocytoma managed with active surveillance vs. partial nephrectomy
Urologic Oncology Seminars and Original Investigations·2022· 3 citedOpen Access
page 1 of 18Next →

Frequent Co-authors

Robert G. Uzzo(28), David Y.T. Chen(21), Rosalia Viterbo(20), Alexander Kutikov(18), Elizabeth R. Plimack(13), Marc C. Smaldone(12), Stephen A. Boorjian(11), Mark K. Buyyounouski(9), Daniel Canter(9), Alexandra L. Hanlon(8), Philippe E. Spiess(8), Neeraj Agarwal(8), Harry W. Herr(8), Subodh M. Lele(8), Jeff M. Michalski(8), Anthony Patterson(8), Wade J. Sexton(8), Eric M. Horwitz(8), Benjamin Movsas(8), Lance C. Pagliaro(7)